(Q37101657)

18 August 2017

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis (English)

1 reference

18 August 2017

0 references

3

John P Bilezikian

1 reference

18 August 2017

5

Kristine E Ensrud

1 reference

18 August 2017

7

Dennis M Black

1 reference

18 August 2017

1

Diana M Antoniucci

1 reference

18 August 2017

4

Lisa Palermo

1 reference

18 August 2017

6

Susan L Greenspan

1 reference

18 August 2017

Deborah E Sellmeyer

2

1 reference

PMCID

3746103

18 August 2017

language of work or name

English

0 references

publication date

12 December 2006

1 reference

The Journal of Clinical Endocrinology and Metabolism

18 August 2017

1 reference

18 August 2017

92

1 reference

18 August 2017

3

1 reference

18 August 2017

942-947

1 reference

Clinical use of bone densitometry: scientific review

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

Interpretation of serum calcium in patients with abnormal serum proteins.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746103

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

3 September 2018

1 reference

12 December 2020

A method for the determination of the circulating concentration of 1,25-dihydroxyvitamin D

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels

1 reference

12 December 2020

Identifiers

DOI

10.1210/JC.2006-1788

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

PMCID

3746103